Highlights
- ClearOne shares closed at US$4.78 on 16 November 2026, up 41.84%, with 19.3 million shares traded during the session.
- A Merger agreement announced on 2 July 2026 would combine ClearOne with Cortigent, a Vivani Medical Subsidiary in neuroprosthetics.
- The combined company would be renamed Cortigent Holdings, alongside a planned financing of US$10 million to US$15 million.
- A Nasdaq Hearings Panel date of 17 November 2026 relates to the company's stockholders' Equity requirement for continued listing.
A former audio-conferencing company is attracting attention for what it may become. ClearOne, Inc. (NASDAQ:CLRO) closed at US$4.78 on 16 November 2026, up 41.84%, on Volume of 19.3 million shares, about four times its usual level. The stock's move comes as the company works towards a planned merger with Cortigent, a neuroprosthetics business.
From Audio Conferencing to a Shell Structure
ClearOne sold its operating Assets to Biamp on 24 October 2025 and has since had no continuing operating revenue, a position reflected in its third-quarter 2026 report. Its future direction depends on the proposed combination.
The stock's relative volume of 4.25 indicates trading well above the recent average, a pattern often seen around corporate transactions that are still awaiting completion.
The Planned Cortigent Merger
On 2 July 2026, ClearOne announced a merger agreement with Cortigent, a subsidiary of Vivani Medical. Cortigent develops neuroprosthetic technology, including the Orion cortical visual prosthesis system, which is designed to provide a form of vision to people with profound blindness.
Under the plan, the combined company would be renamed Cortigent Holdings and seek a new ticker, CRGT. The transaction is expected to be accompanied by a financing of US$10 million to US$15 million, and Vivani is expected to hold a majority stake after closing. The deal remains subject to Shareholder approval, Nasdaq requirements and other conditions.
The Orion system aims to stimulate the visual cortex directly, bypassing damaged eyes or optic nerves, which makes it a distinct approach from retinal implants. Development of such devices typically requires multi-year clinical programmes and regulatory approvals before commercial availability.
Nasdaq Listing Status
A Nasdaq Hearings Panel date of 17 November 2026 relates to the stockholders' equity requirement. The outcome of that process, together with the completion of the merger, will influence the company's continued listing.
Reverse mergers of this type generally require the combined entity to satisfy Nasdaq's initial listing standards, so Capital raised at or around closing is often central to whether a listing continues.
Sector Context and Risks
Neuroprosthetics is an early-stage field in which regulatory milestones, clinical evidence and funding determine progress. Merger completion, financing terms, dilution and listing standards all remain uncertain, and share prices for companies in this position can move sharply.
Investors may follow filings covering the shareholder vote, the financing, the Nasdaq panel decision and any further development of the Orion system.
Investors will also want to see how the shareholder vote and the timing of closing align with the Nasdaq process.
_11_17_2026_06_50_14_402066.jpg)





Please wait processing your request...